(BUSINESS WIRE) – Luminex Trading & Analytics LLC, a buy-side owned trading venue which seeks to deliver the benefits of low cost and more efficient trading, today announced that it has completed its previously announced CEO transition, and has expanded its leadership team with the appointments of four key executives. Luminex plans to open for trading in the fourth quarter of 2015 as a new, independent platform for investment managers with a long term focus to trade large blocks of stock with other investment managers.
Jonathan A. Clark has assumed the role of permanent CEO effective today replacing interim CEO Michael S. Cashel who will return to his position of SVP of Fidelity Trading Ventures. Mr. Cashel will continue to serve in an advisory capacity to Luminex, as needed.
“On behalf of the Luminex Board I would like to thank Mike for his tremendous efforts in establishing Luminex and positioning the company for a successful launch,” said Kevin Cronin, Luminex Board member and Global Head of Trading of Invesco Advisers, Inc. “With the appointments of Jon and his team, we have delivered on our commitment to bring independent leadership to Luminex and we look forward to the opportunity to provide the buy-side with an efficient and low cost trading platform as we progress toward launch.”
Jonathan A. Clark, CEO of Luminex, commented, “I am excited to assume the role of CEO and look forward to bringing the unique benefits of the Luminex platform to our clients. Client interest is robust as the prospect of a well-capitalized, independent platform which provides a low-cost, transparent solution for block trading clearly resonates with investors. I am confident in the tremendous talent we have added to our leadership team and look forward to a successful launch of trading in the fourth quarter.”
In addition to the CEO transition, Luminex also announced the appointment of the following key leaders:
Brian Williamson has been appointed Head of Sales and will be responsible for working directly with Luminex’s clients to ensure a positive customer experience while continuing to build the Luminex client base. Mr. Williams has extensive experience in trading and relationship management including with Liquidnet, where he served as a Senior Global Relationship Manager, and with The Boston Company, where he was Vice President for Equity Trading.
James C. Dolan, has been appointed Chief Compliance Officer with responsibility for Luminex’s regulatory and market compliance, as well as the further development of the firm’s internal compliance infrastructure. Mr. Dolan has an extensive background in top compliance roles, including nearly twenty years with NASD (FINRA), where he led the insider trading investigations program, among other roles. Prior to joining Luminex, Mr. Dolan was at Fidelity since 2007, most recently serving as Vice President of Compliance for Fidelity Institutional, supporting the Prime Brokerage Services, Securities Finance, Fixed Income, International Equity, and Forex businesses of Fidelity Capital Markets.
David Hagen has been appointed as Head of Product where he will oversee Luminex’s product development efforts and will chair the Luminex Advisory Council. Prior to joining Luminex, Mr. Hagen was a Director at Pico Quantitative Trading, focused on expanding Pico’s services to the Institutional trading community. His previous experience includes nine years at Linedata as both Director of Strategic Accounts & Trading and VP Global Trading Technologies, and at the Boston Stock Exchange, where he held the roles of specialist and Head Trader.
Daniel J. Consigli has joined Luminex as the firm’s controller. Mr. Consigli has over 20 years of finance and operational experience at financial institutions. He most recently served as a divisional financial officer at IDB Bank and previously held finance, operational and consulting roles at J.P. Morgan Chase, Resources Global, Pioneer Investment Management and Fidelity Investments.
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”